In particular, therapy aimed at the programmed cell death 1 (PD-1) and the cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) pathways are currently being studied in numerous clinical trials in ovarian cancer [90,91]. Here, CTLA4 is linked to ovarian carcinoma.